News

Irving, Texas-based Reata Pharmaceuticals, Inc. has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for its pulmonary arterial hypertension (PAH) treatment. The FDA’s Office of Orphan Products Development (OOPD) awarded the designation to bardoxolone methyl due to its novel…

April has been named the month for highlighting the importance of organ donation for those living with pulmonary hypertension (PH). The Pulmonary Hypertension Association (PHA) is celebrating Donate Life Month to encourage people to become organ donors and be aware of the need for early screening, diagnosis, and treatment of the disease. The PHA depends on…

The Pulmonary Hypertension Association (PHA), for the 12th consecutive year, has received a 4-star rating from Charity Navigator — the premier evaluator of charities in the United States. This premium designation indicates that PHA adheres to sound fiscal management, good governance, transparency, commitment to accountability and other best practices,…

In a new study entitled “Relationship between pulmonary hypertension, peripheral vascular calcification, and major cardiovascular events in dialysis patients,” the authors identify a relation between pulmonary hypertension and increase risk for cardiovascular problems in dialysis patients. The study was published in the journal for…

The Montreal Heart Institute is currently recruiting patients for a Phase-IIc clinical trial that is evaluating the safety of PulmoBind in participants with pulmonary hypertension and its potential to detect abnormal pulmonary circulation associated within pulmonary hypertension. (ClinicalTrials.gov Identifier: NCT02216279). Pulmonary hypertension is a condition that causes gradual loss…

Dublin, Ireland-based pharmaceutical company Actavis plc has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) regarding its generic version of the drug Letairis, originally marketed by Gilead Sciences, Inc. The company is now waiting for the decision from the FDA on…

A research team from Brigham and Women’s Hospital (BWH) recently made significant advances in understanding what causes Pulmonary hypertension (PH). The study published in the journal EMBO Molecular Medicine has important implications for the diagnosis, treatment, and prevention of PH in people at-risk of developing the disease.

Affecting more than 80 million Americans each year, poor sleep quality has been associated with increased risks of stroke, dementia, headaches and several cardiovascular issues, including atrial fibrillation, and heart failure. Sleep disorders are also believed to be a factor contributing to pulmonary hypertension. Despite increasing numbers of people diagnosed…

A new pilot clinical trial for Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) is now recruiting participants – U.S. veterans between 40 to 85 years old and suffering from Chronic Obstructive Pulmonary Disease who are willing to participate (the study accepts both males and females). The study is entitled…

The Pulmonary Hypertension Association (PHA) has publicly announced its support for the Patients’ Access to Treatments Act (PATA), which is currently being debated in the U.S. House of Representatives. The bi-partisan legislation was presented last week by representatives David B. McKinley (R-WV) and Lois Capps (D-CA) and is designed to reduce…

Actelion recently announced that it has received marketing approval for Opsumit®, the trade name for macitentan, as a treatment for pulmonary arterial hypertension (PAH) from Japan’s Ministry of Health Labor and Welfare. This approval was supported by data collected from a local assessment conducted in Japan and data from the SERAPHIN study, a…

A recent study published in the journal PLoS One found that a single dose of Sildenafil is not associated with clinical improvement of right ventricular (RV) function as measured by cardiovascular magnetic resonance (CMR) in patients with PH-related heart failure (HF). Heart failure…